Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan

10/22/2020 | 12:56am EST
FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug  approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo

TOKYO (Reuters) - Japan's Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.

Carelink will use Fujifilm's data on Avigan's treatment of novel coronavirus infections and influenza to seek imported drug approval in China, Fujifilm said in a statement. The two companies also plan to develop an injectable form of the drug.

Fujifilm said last week it was seeking approval for Avigan as a treatment for COVID-19 in Japan. That followed results from a late-stage study in Japan that showed the antiviral drug reduced recovery time for patients with non-severe symptoms.

Avigan, originally developed as an emergency flu drug and known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Fujifilm sold global rights in July on Avigan to India's Dr Reddy's Laboratories and Dubai-based Global Response Aid. That deal excluded China, Japan and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

(Reporting by Rocky Swift; Editing by Christian Schmollinger and Muralikumar Anantharaman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -0.37% 5033.8 End-of-day quote.-3.27%
FUJIFILM HOLDINGS CORPORATION 1.60% 6287 End-of-day quote.15.61%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.07% 75.172 Delayed Quote.0.19%
Latest news "Economy & Forex"
01:02aChina's strong economic performance good sign for global recovery, says scholar
PU
01:02aCENTRAL PEOPLE GOVERNMENT OF PEOPLE RE : Economic powerhouse Guangdong sets 6% target for GDP growth
PU
01/23New Zealand probes first 'probable' community COVID-19 case in months
RE
01/23Chile regrets panic triggered by mistaken tsunami warning after quake
RE
01/23Strong tremor felt in chilean capital santiago - reuters witnesses
RE
01/23Chile's interior ministry issues tsunami warning following earthquake off antarctica
RE
01/23OFFICE OF JUVENILE JUSTICE AND DELINQUENCY PREVENT : Notice of Cancellation and Intent to Repost Select Fiscal Year 2021 Solicitations
PU
01/23UK to quarantine visitors from nations with high COVID-19 risk, Daily Mail says
RE
01/23UK extends councils' lockdown powers until July 17, Telegraph says
RE
01/23Biden administration to unveil more climate policies, urges China to toughen emissions target
RE
Latest news "Economy & Forex"